Bridgewater Associates LP Reduces Holdings in DaVita Inc. (NYSE:DVA) (2024)

Bridgewater Associates LP cut its position in DaVita Inc. (NYSE:DVA – Free Report) by 2.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 110,855 shares of the company’s stock after selling 2,213 shares during the quarter. Bridgewater Associates LP’s holdings in DaVita were worth $11,613,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its holdings in DaVita by 1.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 15,088 shares of the company’s stock worth $1,426,000 after buying an additional 153 shares in the last quarter. Kingswood Wealth Advisors LLC bought a new stake in DaVita in the fourth quarter valued at about $2,831,000. Truist Financial Corp raised its stake in DaVita by 54.4% during the fourth quarter. Truist Financial Corp now owns 26,068 shares of the company’s stock valued at $2,731,000 after buying an additional 9,180 shares in the last quarter. Raymond James & Associates raised its stake in DaVita by 135.2% during the fourth quarter. Raymond James & Associates now owns 34,376 shares of the company’s stock valued at $3,601,000 after buying an additional 19,759 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its holdings in DaVita by 108.8% during the 4th quarter. Handelsbanken Fonder AB now owns 16,700 shares of the company’s stock worth $1,749,000 after buying an additional 8,700 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on DVA shares. Truist Financial upped their price target on DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, May 15th. StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Barclays boosted their price objective on shares of DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research report on Monday, May 6th. Finally, UBS Group raised their target price on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, DaVita has a consensus rating of “Moderate Buy” and a consensus target price of $144.67.

View Our Latest Stock Analysis on DaVita

DaVita Stock Performance

DVA stock opened at $139.86 on Wednesday. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $147.93. The stock has a market capitalization of $12.27 billion, a price-to-earnings ratio of 15.89, a PEG ratio of 1.08 and a beta of 0.96. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43. The stock’s fifty day moving average is $136.87 and its two-hundred day moving average is $123.17.

DaVita (NYSE:DVA – Get Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.43. The firm had revenue of $3.07 billion for the quarter, compared to the consensus estimate of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. DaVita’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period last year, the firm posted $1.58 EPS. On average, research analysts predict that DaVita Inc. will post 9.62 EPS for the current year.

Insider Activity

In related news, Director Barbara J. Desoer sold 5,030 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the completion of the transaction, the director now directly owns 10,954 shares of the company’s stock, valued at approximately $1,520,524.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.00% of the company’s stock.

DaVita Company Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

See Also

• Five stocks we like better than DaVita
• Utilities Stocks Explained – How and Why to Invest in Utilities
• Can Viking Holdings Extend Gains from Affluent Cruisers?
• 3 Warren Buffett Stocks to Buy Now
• Can Southwest Airlines Stock Truly Rally 77% on Activist Plans?
• Overbought Stocks Explained: Should You Trade Them?
• Apple Stock’s All-Time High: Can AI Outweigh Earnings Jitters?

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.